Clinical efficacy of atezolizumab plus bevacizumab combined with local therapy for the treat-ment of recurrent hepatocellular carcinoma before liver transplantation
10.3760/cma.j.cn115610-20220908-00501
- VernacularTitle:阿替利珠单克隆抗体与贝伐珠单克隆抗体联合局部治疗在复发性肝癌肝移植前治疗中的临床疗效
- Author:
Zeyang LIU
1
;
Tingxiao ZHANG
;
Gang DU
;
Qianqian XU
;
Jianlei WANG
;
Tong XIA
;
Mingkun LIU
;
Bin JIN
Author Information
1. 山东大学齐鲁医院器官移植科，济南 250012
- Keywords:
Liver neoplasms;
Liver transplantation;
Preoperative downstaging;
Local therapy;
Immunotherapy;
Transplantation rejection
- From:Chinese Journal of Digestive Surgery
2022;21(S1):20-24
- CountryChina
- Language:Chinese
-
Abstract:
Downstaging treatment by local therapy combined with systemic therapy before liver transplantation for patients with recurrent hepatocellular carcinoma (HCC) can control tumor progression and reduce tumor burden, which resulting in reducing the push-out rate of patients during the waiting period for liver transplantation, providing an oncological observation window, enabling patients of beyond Milan criteria downstaged with better survival benefit. The authors introduce the clinical experience of a case with recurrent HCC of beyond Milan criteria who under-went liver transplantation after receiving atezolizumab plus bevacizumab combined with local therapy. Results show the patient achieving pathological complete remission without postoperative rejection and obtaining a good prognosis with life status improved.
